Gout Treatment: A Complete Guide for NP Board Exam Prep
Last updated: June 2026 — Reviewed by Shaira Cohen, MSN, APRN, FNP-C, CNE*
Gout is one of the most heavily tested rheumatology topics on the nurse practitioner board exams, and for good reason — it is the most common inflammatory arthritis, and management has clear, guideline-driven answers. If you understand the difference between treating an acute gout flare and providing long-term urate-lowering therapy, you can reliably answer most gout questions on the AANP or ANCC exam.
This guide breaks gout treatment into the two phases examiners care about, walks through drug selection by comorbidity, explains the treat-to-target strategy, and finishes with board-style practice questions.
Understanding Gout: Why Treatment Has Two Phases
Gout results from the deposition of monosodium urate crystals in joints and soft tissue when serum urate exceeds its saturation point of roughly 6.8 mg/dL. Those crystals trigger intense inflammation, producing the classic hot, swollen, exquisitely tender joint — most often the first metatarsophalangeal joint (podagra).
The critical concept for boards is that gout treatment has two separate goals that should not be confused:
- Treat the acute flare — stop the inflammation and pain quickly.
- Lower serum urate long-term — prevent future flares, tophi, and joint damage.
Anti-inflammatory drugs treat the flare but do nothing to the underlying urate level. Urate-lowering drugs prevent flares but do not treat an active one — and can even trigger a flare when first started. Mixing these up is a classic exam trap.
Treating an Acute Gout Flare
The goal of acute gout treatment is rapid control of inflammation. Start therapy as early as possible — ideally within 24 hours of symptom onset. There are three first-line options, and they are considered roughly equivalent in efficacy; selection is driven by patient comorbidities.
NSAIDs
Full anti-inflammatory doses of an NSAID (such as naproxen or indomethacin) are effective for otherwise healthy patients. Avoid NSAIDs in patients with chronic kidney disease, heart failure, active peptic ulcer disease, or anticoagulation.
Colchicine
Colchicine works best when started early in the flare. Current guideline dosing for an acute flare is 1.2 mg at the first sign of a flare, followed by 0.6 mg one hour later (total 1.8 mg on day one). Dose-related diarrhea is the most common adverse effect, and colchicine requires dose adjustment in renal impairment and interacts with strong CYP3A4 inhibitors.
Corticosteroids
Oral prednisone, or an intra-articular injection when only one or two joints are involved, is preferred when NSAIDs and colchicine are contraindicated — for example, in a patient with advanced CKD. Always rule out septic arthritis before injecting a steroid into a joint.
For flares refractory to these options, IL-1 inhibitors (anakinra, canakinumab) are an alternative.
Board pearl: Do not stop a patient's existing urate-lowering therapy during a flare. Current ACR guidance also permits starting urate-lowering therapy during a flare, as long as anti-inflammatory coverage is in place — but the patient's chronic allopurinol should never be interrupted because of a flare.
Long-Term Urate-Lowering Therapy
Once the flare settles, the question becomes whether the patient needs ongoing urate-lowering therapy (ULT). ULT is the only way to dissolve crystal deposits and prevent recurrent disease.
Who Needs Urate-Lowering Therapy?
ULT is strongly recommended for patients with any of the following:
- One or more subcutaneous tophi
- Radiographic damage attributable to gout
- Frequent flares — generally two or more per year
ULT is conditionally recommended for a patient who has had a first flare and also has chronic kidney disease (stage 3 or worse), a serum urate above 9 mg/dL, or a history of urolithiasis.
First-Line Agent: Allopurinol
Allopurinol, a xanthine oxidase inhibitor, is the recommended first-line ULT for all patients, including those with CKD. Key prescribing principles tested on boards:
- Start low and titrate slowly. Begin at no more than 100 mg/day (50 mg/day in CKD) and increase gradually to reach the target urate level. Starting low reduces the risk of triggering a flare and of hypersensitivity.
- Consider HLA-B*5801 testing before starting allopurinol in higher-risk populations — patients of Southeast Asian or African descent — because of the elevated risk of severe cutaneous reactions (Stevens-Johnson syndrome / toxic epidermal necrolysis).
Alternative Agents
- Febuxostat is an alternative xanthine oxidase inhibitor for patients who cannot tolerate allopurinol. It carries an FDA warning regarding cardiovascular risk, so it is generally reserved rather than used first-line.
- Probenecid, a uricosuric agent, increases renal urate excretion; it is less effective in significant renal impairment and is avoided in patients with a history of kidney stones.
- Pegloticase, an intravenous recombinant uricase, is reserved for severe, refractory, tophaceous gout.
Treat-to-Target and Flare Prophylaxis
Gout management follows a treat-to-target strategy. The serum urate goal is less than 6 mg/dL, and less than 5 mg/dL for patients with tophi or severe disease. Titrate the ULT dose and recheck urate until the target is met.
When ULT is first started, mobilizing crystals can paradoxically trigger flares. To prevent this, give anti-inflammatory prophylaxis — low-dose colchicine (0.6 mg once or twice daily), a low-dose NSAID, or low-dose prednisone — for three to six months after starting ULT.
"Drill gout and rheumatology questions in the NP Question Bank"
Comparison of Urate-Lowering Agents
| Agent | Class | First-Line? | Key Consideration |
|---|---|---|---|
| Allopurinol | Xanthine oxidase inhibitor | Yes | Start low, titrate; consider HLA-B*5801 testing in high-risk groups |
| Febuxostat | Xanthine oxidase inhibitor | No | Alternative; cardiovascular safety warning |
| Probenecid | Uricosuric | No | Avoid in renal impairment and kidney stones |
| Pegloticase | Recombinant uricase (IV) | No | Reserved for refractory tophaceous gout |
Lifestyle and Patient Education
Diet alone rarely controls gout, but lifestyle counseling supports pharmacologic treatment and is testable. Advise patients to:
- Limit alcohol, especially beer and spirits
- Reduce high-fructose corn syrup and sugar-sweetened beverages
- Moderate purine-rich foods — red meat, organ meat, and certain shellfish
- Lose weight if overweight and stay well hydrated
Examiners may also expect you to review the medication list: thiazide and loop diuretics and low-dose aspirin raise serum urate and may need reassessment.
Board-Style Practice Questions
1. A patient with stage 4 chronic kidney disease presents with an acute gout flare of the right great toe. Which acute treatment is most appropriate?
Show Answer
2. A patient is started on urate-lowering therapy. What is the target serum urate level for most patients with gout?
Show Answer
3. When initiating allopurinol, what should be co-prescribed and for how long?
Show Answer
4. A patient on chronic allopurinol develops an acute flare. Should the allopurinol be stopped?
Show Answer
FAQ
What is the best treatment for gout?
How do you get rid of a gout flare quickly?
What is the first-line treatment for an acute gout flare?
When should urate-lowering therapy be started for gout?
What is the target serum urate level in gout treatment?
Should allopurinol be stopped during a gout flare?
Why is anti-inflammatory prophylaxis used when starting allopurinol?
Conclusion
The key to gout treatment questions on the NP boards is separating the two phases: anti-inflammatory drugs control the acute flare, and urate-lowering therapy prevents future disease. Choose flare therapy by comorbidity, start allopurinol low and titrate to a serum urate below 6 mg/dL, and always pair new ULT with three to six months of anti-inflammatory prophylaxis.
Want to test yourself under exam conditions? Practice rheumatology and pharmacology questions in The Cohen Review Question Bank, or get full guideline-based coverage with The Full Package board prep course.
Sources:
“Gout Clinical Practice Guidelines.” Rheumatology.org, rheumatology.org/gout-guideline.
